but the R/M and name/ticker change would still be faster and easier.
No, it would not. Ignoring the fact that it is impossible and will not occur, let's put reality aside and somehow say it could. It would still be much more expensive to R/M than IPO. Why? Because all the unpaid liabilities would still be attached to BIOAQ, AND the 120+ million common shares still outstanding. No one is interested in any of those two deadweights, which is why there was ZERO interest during the SISP phase. NO ONE was interested in recapitalizing the stock. They just wanted the assets.
If LCY wants to go public, it would be much cheaper and easier to do so through an IPO. And a Reverse Merger provides ZERO capital to the company (or its current owners), while an IPO does both. And they wouldn't have to share their private company with either the unpaid creditors or the old common shareholders.
Market Data 
Markets 
AI
